Inactive Instrument

Highlights CannPal Animal Therapeutics Limited

Equities

CP1

AU000000CP17

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Layton Mills and Margaret Curtis agreed to acquire 52% stake in CannPal Animal Therapeutics Limited from AusCann Group Holdings Ltd for AUD1.	23-03-09	CI
AusCann Group Holdings Ltd completed the acquisition of CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others.	21-03-10	CI
Cannpal Animal Therapeutics : Narrows Fiscal H1 Loss on Higher Revenue	21-02-19	MT
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2020	21-02-18	CI
AusCann : CannPal Managing Director to Lead Merged Company Formed With AusCann; CannPal Rises 11%	21-01-07	MT
AusCann Group Holdings Ltd entered into a scheme implementation deed to acquire CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others for AUD 16.9 million.	20-11-15	CI
CannPal Animal Therapeutics Limited Announces Completion of its Safety and Efficacy Study for DermaCann	20-07-20	CI
CannPal Animal Therapeutics Limited Announces FDA Establishes Investigational New Animal Drug file for CPAT-01	20-03-10	CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2019	20-02-25	CI
CannPal Animal Therapeutics Limited Enters into Exclusive Licensing Agreement with Commonwealth Scientific and Industrial Research Organisation	20-01-05	CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2019	19-08-30	CI
CannPal Animal Therapeutics Limited Commences Phase 2 Pilot Study for Cannabis-Derived Osteoarthritis Drug for Dogs	19-07-31	CI
Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2018	19-02-25	CI
CannPal Animal Therapeutics Limited Receives Key Ethics Approvals for CPAT-01 Phase 2A Study and Dermacann Skin Study	19-02-12	CI
Cannpal Animal Therapeutics Limited Completes Phase 1B Cannabinoid Study in Dogs	18-12-11	CI
Cannpal Animal Therapeutics Limited Receives US FDA Sponsor Fee Waiver for Lead Drug Candidate CPAT-01	18-09-23	CI
Cannpal Animal Therapeutics Limited Commences Phase 1B Study for Lead Drug Candidate CPAT-01D	18-09-02	CI
Cannpal Animal Therapeutics Limited Announces Earnings Results for the Year Ended June 30, 2018	18-08-30	CI
CannPal Animal Therapeutics Limited Enters Memorandum of Understanding with the University of Melbourne	18-08-07	CI
CannPal Animal Therapeutics Limited Receives Ethics Approval for Phase 1B Dog Study	18-08-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CannPal Animal Therapeutics Limited

Equities

CP1

AU000000CP17

Highlights

Filters